REPL (Replimune Group) Cash And Cash Equivalents : $172.25 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Replimune Group Cash And Cash Equivalents?

Replimune Group's quarterly cash and cash equivalents declined from Jun. 2024 ($151.66 Mil) to Sep. 2024 ($113.49 Mil) but then increased from Sep. 2024 ($113.49 Mil) to Dec. 2024 ($172.25 Mil).

Replimune Group's annual cash and cash equivalents increased from Mar. 2022 ($105.95 Mil) to Mar. 2023 ($146.59 Mil) but then declined from Mar. 2023 ($146.59 Mil) to Mar. 2024 ($74.46 Mil).

Replimune Group Cash And Cash Equivalents Historical Data

The historical data trend for Replimune Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replimune Group Cash And Cash Equivalents Chart

Replimune Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

59.50

182.52

105.95

146.59

74.46

Replimune Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															97.67	74.46	151.66	113.49	172.25

Replimune Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Replimune Group (NAS:REPL) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Replimune Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Replimune Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Replimune Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Replimune Group Inc (NAS:REPL) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

7R8:Germany

Address

500 Unicorn Park Drive, Suite 303, Woburn, MA, USA, 01801

Website

https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Executives

Sushil Patel	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Christopher Sarchi	officer: Chief Commercial Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Konstantinos Xynos	officer: Chief Medical Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Emily Luisa Hill	officer: Chief Financial Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Philip Astley-sparke	director, 10 percent owner, officer: Executive Chairman	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Andrew Schwendenman	officer: Chief Accounting Officer	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Robert Coffin	director, 10 percent owner, officer: President and C.E.O.	C/O BIOVEX GROUP, INC., 34 COMMERCE WAY, WOBURN MA 10801
Love Colin	10 percent owner, officer: Chief Operating Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 10801
Pamela Esposito	officer: Chief Business Officer	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Tanya Lewis	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON MA 02459
Veleka Peeples-dyer	director	C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, WOBURN MA 01801
Jean M. Franchi	officer: Chief Financial Officer	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Omega Fund Iv Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Jason P Rhodes	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139